Oncology & Cancer

Need for national Canadian strategy for EGFR testing

Significant advances have taken place in the management of patients with advanced and metastatic non–small-cell lung cancer (NSCLC) over the last 5 years. Traditionally, all advanced NSCLC patients were treated in a similar ...

Oncology & Cancer

Tumors with ALK rearrangements can harbor more mutations

The identification of potentially targetable kinase mutations has been an exciting advancement in lung cancer treatment. Although the mutations driving many lung carcinomas remain unknown, approximately 50 percent of lung ...

page 1 from 2


Gefitinib INN ( /ɡɛˈfɪtɨnɪb/), trade name Iressa, is a drug used in the treatment of certain types of cancer, particularly those with mutated and overactive EGFR. Gefitinib is an EGFR inhibitor, like erlotinib, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells. It is marketed by AstraZeneca and Teva.

This text uses material from Wikipedia, licensed under CC BY-SA